Study: Many men take dietary supplements to prevent prostate cancer

May 06, 2004

A significant percentage of men take dietary supplements such as vitamins, minerals and herbs to prevent prostate cancer despite a lack of evidence that they work. That is the result of a new study published by Fox Chase Cancer Center researchers in the May issue of the British Journal of Urology International.

"More than half of the men in our study say they take natural products believed to reduce their chances of developing prostate cancer," says Robert G. Uzzo, M.D., a urologic surgeon at Fox Chase Cancer Center and lead author of the study. "Although the preventative effectiveness of many of these supplements is not established, they are widely perceived by the public to lower the risk of developing prostate cancer."

The study evaluated questionnaires given to 333 men upon enrollment into Fox Chase's Prostate Cancer Risk Assessment Program (PRAP). Those eligible for PRAP include African American men and any man with a family history of prostate cancer. The 420-item self-administered questionnaire included questions about the use of nutritional supplements and complementary therapies. Supplemental use was divided into eight categories including vitamins, minerals, and extracts from fruits/seeds, organic compounds, flowers/bulbs, leaves/bark, roots, or animal products.

More than half (51%) of the men who completed the questionnaire reported taking one or more supplements to prevent prostate cancer. Most commonly used were vitamins such as A, B, C, D, and E (95%), minerals such as zinc, calcium and selenium (28%), and fruit/seed extracts such as saw-palmetto, soy isoflavones and flax seed (18%). More than one in four men (27%) took three or more agents.

"The use of vitamin and nutrient supplements for prostate cancer prevention has received a great deal of attention from marketers and the popular media," says Uzzo. "The use of vitamins, minerals and extracts represents a unique cultural phenomenon. The lure of complementary therapies may be in their non-Western nature. That is, their claim to be effective is often based on theories outside of Western medical science."

Currently, researchers at Fox Chase Cancer Center and elsewhere are enrolling volunteers in a nationwide study to determine if the trace mineral selenium and vitamin E, either alone or in combination, can prevent prostate cancer. The study is ongoing and results will not be known for several years.

Uzzo believes the use of supplements outside of a clinical trial is being done so in a complementary role, rather than as a substitute for conventional therapy. He says nutritional supplements are generally felt to be "natural" and therefore, have no side effects when many do.

"Side effects can occur when people take too much selenium, vitamin D or zinc, and there can also be unanticipated interactions with conventional therapies," Uzzo explained. "Other studies suggest that up to 71 percent of patients may not inform their physicians about their use of herbs, so it is important for patients and physicians to talk about the use of herbs in order to avoid potential problems."
-end-
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.

Fox Chase Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.